Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.60

-1.1%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$278.10M
EPS-1.4000
P/E Ratio-1.97
Earnings Date08/12/2026

catx

Total Current Liabilities

Last Annual Value

28.68M

3-Year CAGR

120%

5-Year CAGR

85%

10-Year CAGR

39%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of Total Current Liabilities

CATX · AMEX
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
28.68M
22.3%73.1%38.5% 
11.50M
-7.8%12.5%N/A
10.47M
9.1%17.7%13.0%
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
14.27M
-7.2%-1.8%9.7%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
34.16M
-12.1%-11.3%N/A
30.52M
15.5%14.2%8.6%
HSDT logo
Solana Company
NASDAQ:HSDT
3.02M
17.1%2.6%N/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.6, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.6